External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Targeted M&amp;A and Strategic Expansion in European Regulated Markets: Marksans Pharma has strengthened its long-term growth strategy through front-end European acquisitions, including Netherlands-based QliniQ B.V. and Germany-based GmbH, alongside establishing operating entities in Ireland and Germany.</li><li>The transactions broaden the company's product portfolio beyond traditional store-brand over-the-counter (OTC) drugs to include high-margin prescription (Rx) formulations across regulated European markets.</li><li>Backed by a net cash balance of Rs 1,058 Cr, management is targeting Rs 1,000 Cr in European revenues over the next 3–5 years. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Targeted M&amp;A and Strategic Expansion in European Regulated Markets: Marksans Pharma has strengthened its long-term growth strategy through front-end European acquisitions, including Netherlands-based QliniQ B.V. and Germany-based GmbH, alongside establishing operating entities in Ireland and Germany.The transactions broaden the company's product portfolio beyond traditional store-brand over-the-counter (OTC) drugs to include high-margin prescription (Rx) formulations across regulated European markets.Backed by a net cash balance of Rs 1,058 Cr, management is targeting Rs 1,000 Cr in European revenues over the next 3–5 years. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Axis Punch: Marksans Pharma Ltd - 31st August, 2026

External broker reports(aggregated public sources), Nirmal Bang

Nirmal Bang

A Relationship Beyond Broking

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

<div><div><div><div><ul><li>Efforts around portfolio selection and disciplined R&amp;D has helped the company profitably build its export formulations business</li></ul><div><div><div><ul><li>Outlook: The company will incur capital expenditure on its existing facility upgradation; and it is also open to pursuing an acquisition (~Rs2,000mn is the allocation).</li></ul><div><div><div><div><ul><li>Targeting customer acquisition and geographic expansion in the US market: The company has added new retailers in the US market with an intention to penetrate tier 2 &amp; tier 3 cities.</li></ul></div></div></div></div></div></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Efforts around portfolio selection and disciplined R&amp;D has helped the company profitably build its export formulations businessOutlook: The company will incur capital expenditure on its existing facility upgradation; and it is also open to pursuing an acquisition (~Rs2,000mn is the allocation).Targeting customer acquisition and geographic expansion in the US market: The company has added new retailers in the US market with an intention to penetrate tier 2 &amp; tier 3 cities.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India

Marksans Pharma Limited manufactures active ingredients that are used to produce finished drugs.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Marksans Pharma (MRKS IN)

Axis Punch: Marksans Pharma Ltd - 31st August, 2026

Marksans Pharma has strengthened its long-term growth strategy through front-end European acquisitions, including Netherlands-based QliniQ B.V. and...

Axis Direct

Marksans Pharma- Management Meet Update

We hosted the management of Marksans Pharma at our Annual Investor Conference to get an overview on business outlook in the backdrop of the current...

Nirmal Bang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)